Glutamate and the N-methyl-D-aspartate receptor ligand D-serine are putative gliotransmitters. Here, we show by immunogold cytochemistry of the adult hippocampus that glutamate and Dserine accumulate in synaptic-like microvesicles (SLMVs) in the perisynaptic processes of astrocytes. The estimated concentration of fixed glutamate in the astrocytic SLMVs is comparable to that in synaptic vesicles of excitatory nerve terminals (~45 and~55 mM, respectively), whereas the D-serine level is about 6 mM. The vesicles are organized in small spaced clusters located near the astrocytic plasma membrane. Endoplasmic reticulum is regularly found in close vicinity to SLMVs, suggesting that astrocytes contain functional nanodomains, where a local Ca 21 increase can trigger release of glutamate and/or D-serine.
Introduction
Astrocytes contain a variety of transmitter receptors enabling them to respond to neuronal activity by increasing the intracellular Ca 2+ concentration ([Ca 2+ ] i ) (Dani et al. 1992; Pasti et al. 1997; Wang et al. 2006) . Such a [Ca 2+ ] i increase triggers release of a variety of signaling substances, including glutamate, purines, D-serine, eicosanoids, and tumor necrosis factor alpha (TNF-a) (Volterra and Meldolesi 2005) . Evidence suggests that glutamate and D-serine are released from astrocytes via Ca 2+ -dependent exocytosis (for review, see Oliet and Mothet 2008; Santello and Volterra 2009) . The existence of a tightly regulated mechanism of glutamate release in astrocytes (Bezzi et al. 2004; Marchaland et al. 2008 ) is consistent with data indicating that these cells play rapid and precise roles in neuromodulation (Jourdain et al. 2007; Perea and Araque 2007; Santello et al. 2011 ) and neurovascular coupling (Winship et al. 2007; Schummers et al. 2008 ). However, conflicting data have been presented (Fiacco et al. 2007; Li et al. 2008; Petravicz et al. 2008; Agulhon et al. 2010) , questioning the existence of rapid gliotransmitter exocytosis from astrocytes serving physiological neuromodulation (Agulhon et al. 2008; Fiacco et al. 2009 ). To resolve this controversy, there is a need to provide direct in situ evidence of glutamatecontaining vesicles in adult astrocytes. As for D-serine, data suggest that this amino acid is released from astrocytes to act as an endogenous N-methyl-D-aspartate (NMDA) receptor coagonist at central synapses (Panatier et al. 2006; Oliet and Mothet 2008 , but see Rosenberg et al. 2010) . Moreover, astrocyte D-serine was recently found to be essential for the establishment of NMDA receptor--dependent long-term potentiation (LTP) in the hippocampus (Henneberger et al. 2010) . However, it is not known whether D-serine is stored in vesicles of astrocytes in situ, although in vitro evidence indicates that Dserine and glutamate could be contained in similar vesicular organelles (Martineau et al. 2008) . Here, we address these questions by using high-resolution quantitative immunogold cytochemistry with specific antibodies to glutamate and Dserine.
Materials and Methods

Perfusion Fixation and Antibody Specificity
Rats derived from the Wistar strain (4--5 weeks) were anesthetized with pentobarbital (100 mg/kg) before fixation through transcardiac perfusion (50 mL/min for 15 min) with a mixture of 4% formaldehyde and 0.5% glutaraldehyde (glutamate/EEAT2, glutamate/VGLUT1, and Dserine/VGLUT1 immunocytochemistry, n = 3 rats) or 2.5% glutaraldehyde and 1% formaldehyde (D-serine/EAAT2 and glutamate/D-serine immunocytochemistry, n = 3 rats or morphological analysis, n = 3 rats). For morphological analysis, the fixed tissues were treated with 1% osmium tetroxide before embedding in Durcupan. For immunogold analysis, specimens of hippocampus were cryoprotected with increasing concentrations of glycerol (10%, 20%, and 30%) and embedded in Lowicryl HM20 according to a freeze substitution protocol. Ultrathin sections (50--100 nm) were subjected to either morphological analysis or postembedding immunogold cytochemistry (Bergersen et al. 2008 ) using the following primary antibodies: rabbit anti-glutamate (no 607, dilution 1:30 000), rabbit anti-D-serine (no 21 236, dilution 1:2000), rabbit anti-EAAT2 (a mixture of anti-B12, 10 lg/mL and anti-B493, 5 lg/mL), goat anti-EAAT2 antibodies (2 lg/mL, Santa Cruz Biotechnology, Santa Cruz, CA), guinea pig anti-VGLUT1 antibodies (dilution 1:1000 Synaptic Systems), mouse caveolin-1 antibodies (dilution 1:300, BD Biosciences), rabbit anti-calreticulin antibodies (dilution 1:300, AbCam), and mouse anti-glutamine syntehase antibodies (dilution 1:100, BD Biosciences). The anti-glutamate and anti-D-serine antibodies were raised essentially as first described (Storm-Mathisen et al. 1983 ). The 607 glutamate antiserum has been proven to be specific through extensive characterization (Broman et al. 1993; Gundersen et al. 1998 ) and was used with the addition of 0.2 mM glutaraldehyde-and formaldehyde-treated aspartate and glutamine. The 21 236 D-serine antiserum has not been characterized previously. To test the D-serine antibodies, test specimens (Ottersen and StormMathisen 1984) were made by spotting conjugates of about 50 different amino acids and peptides endogenous to the brain, linked to brain proteins by glutaraldehyde/formaldehyde onto cellulose nitrate/acetate filters. The test filters were processed with the D-serine antibodies according to a 3 layer peroxidase--antiperoxidase method. The tested compounds were L-and D-serine, L-and D-homocysteate, D-cysteine, DL-homocysteine, L-citrulline, reduced glutathione,
histidine, L-cysteate, glutamyltaurine, cysteine sulphinate, N-acetylaspartate, oxidized glutathione, L-S-sulpho-cysteine, leu-enkephalin, and met-enkephalin. There was a slight cross-reactivity against L-serine as well as against L-cysteine, which disappeared when the serum was preabsorbed with soluble glutaraldehyde/formaldehyde complexes of these amino acids. In each immunogold experiment, ultrathin test sections (Ottersen 1987) were processed along with the hippocampal sections, ascertaining the specificity of the labeling produced. The test sections were made of conjugates of different amino acids linked to brain macromolecules by glutaraldehyde--formaldehyde, which were freeze dried and embedded in epoxy resin (Ottersen 1987) . In particular, the D-serine antibodies were tested against 12 different amino acids (D-serine, L-cystein, D-cystein, L-valine, a-alanine, glycine, L-serine, L-glutamate, L-aspartate, glutamine, GABA, and taurine) of which only the conjugate-containing D-serine was labeled (see Supplementary  Fig. 1 ).
We also tested the rabbit 87554 D-serine antiserum, which showed quite a strong labeling of the D-serine conjugate but also an additional weak labeling of all the other amino acid conjugates in the electron microscopic ''test sandwich.'' Thus, in this project, we only used the 21 236 D-serine antiserum. In the course of the experiments, we tested 2 commercial rabbit anti-D-serine antisera, one from AbCam (ab 6572; Cambridge, UK) and one from Advanced Targeting Systems (AB-T048; San Diego, CA). Both antibodies produced a strong cross-reactivity against the GABA conjugate in the ultrathin test sections as well as strong labeling of terminals forming symmetrical synapses in the ultrathin tissue sections (not shown). As an extra negative control test, the glutamate and D-serine immunoreactivities of tissue and test sections were blocked by adding 0.3 mM aldehyde-treated glutamate and D-serine to the respective antisera. The rabbit EAAT2 antisera (anti-B12 and anti-B493) have been extensively characterized Beckstrøm et al. 1999) . When tested on western blots of hippocampal homogenates, the VGLUT1 antibodies produced a single band with an appropriate molecular weight of about 65 kDa. In a parallel study, the VGLUT1 antibodies produced strong astrocytic labeling in wild type and weak labeling in VGLUT1 knockout hippocampus (L Ormel, LH Bergersen, V Gundersen, unpublished data) . According to the manufacturer, the caveolin-1, calreticulin, and glutamine synthetase antibodies are specific and give one single band with appropriate molecular weights on western blots of brain tissue.
The rabbit glutamate, rabbit D-serine, and rabbit calreticulin primary antibodies were visualized with goat anti-rabbit (10 nm gold particles, BBI, UK), the rabbit EAAT2 antibodies with goat anti-rabbit (15 nm gold particles, BBI), the goat EAAT2 antibodies with donkey anti-goat (15 nm gold particles, Aurion, the Netherlands), the guinea pig VGLUT1 antibodies with goat anti-guinea pig (15 nm gold particles, BBI), the mouse glutamine synthetase antibodies with goat anti-mouse (15 nm gold particles, BBI), and the mouse caveolin-1 antibodies with goat antimouse (10 nm gold particles, BBI) secondary antibodies. In double labeling immunogold experiments, in which the rabbit EAAT2 antibodies were used, glutamate-or D-serine--labeled sections were treated with formaldehyde vapor (70°C, 1 h) to inactivate unoccupied binding sites on the primary rabbit immunoglobulins, before labeling with the rabbit anti-EAAT2 antibodies. The same approach was used in double labeling for D-serine and glutamate (visualized with the 10 and 15 nm coupled goat anti-rabbit secondary antibodies, respectively). The rabbit anti-EAAT2 and goat EAAT2 antibodies showed similar immunogold labeling patterns. In the quantitative analysis (see below), we used sections that were labeled with the glutamate or D-serine antibodies in the first step and the rabbit EAAT2 antibodies in the second step.
Morphological and Quantitative Immunogold Analysis
Electron micrographs of the ultrathin tissue sections were randomly taken (with a Philips CM 10 or a Tecnai 12 electron microscope) in the outer two-thirds of the dentate molecular layers, which are the termination fields for the perforant path glutamatergic afferents (Amaral and Witter 1989) . All quantifications were done on micrographs magnified at 346 000.
Morphological Analysis
For the morphological analysis, astrocytic processes surrounding asymmetric synapses between nerve terminals and dendritic spines were identified according to published criteria (Peters et al. 1991; Lehre and Danbolt 1998; Ventura and Harris 1999) and by their concave shape and electron lucent appearance. Astrocytic processes included in the analysis had cross-sectional diameters below 800 nm. When the morphological analysis was performed in Lowicryl-embedded tissue, astrocytic processes were also identified by labeling of EAAT2 (Chaudhry et al. 1995; Bezzi et al. 2004 ). Round and clear vesicular structures in perisynaptic astrocytic processes were included in the analysis if they had a diameter between 20 and 80 nm. The perpendicular distance from the astrocytic plasma membrane to the centers of synaptic-like microvesicles (SLMVs) in astrocytic processes was analyzed and frequency histograms made. The number of synaptic vesicles (SVs) in nerve terminals and SLMVs in astrocytic processes were counted. The areas of nerve terminals and astrocytic processes, as well as of clusters of SVs and SLMVs, were determined by point counting using an overlay screen (Bergersen et al. 2008) , and the densities of SVs and SLMVs calculated. The cluster of SVs in nerve terminals was recorded over an area made up by the presynaptic active zone and perpendicular lines (distance of 100 nm) drawn from the end of the active zone; and the cluster of SLMVs in astrocytic processes was recorded over an area made by outlining of the grouped SLMVs (exemplified in Fig. 1 and Supplementary Fig. 2 ).
In addition, to investigate whether the SLMVs are randomly distributed throughout the process or show a regularly spaced organization, a plugin for ImageJ (http://rsb.info.nih.gov/ij/) was used to outline the plasma membrane of the astrocytic process and record the locations of the centers of SLMVs in the profile. Random points (similar numbers as the numbers of SLMVs in the profiles) were placed over the astrocytic profiles 49 times in succession. Recorded coordinates were submitted to a program written in Python (http:// www.python.org) for computation of clusters of SLMVs and random points. An SLMV or a random point was defined as belonging to a cluster if their centers were situated <100 nm from the closest SLMV or random point (see Supplementary Result 1). The distances between the clusters of SLMVs and random points were calculated in the following way: first, perpendicular lines from the cluster centers were drawn to the astrocytic plasma membrane. Then, the distances along the plasma membrane between each SLMV and random point intersection with the plasma membrane were calculated. The statistical significance of the difference between the observed and expected (random points) distributions among bins was evaluated by the chisquare test for known distributions (see Supplementary Result Fig. 1 ).
Glutamate and D-serine Quantifications
For immunogold quantifications of glutamate and D-serine, only the astrocytic processes (identified by morphological criteria) with visible EAAT2-positive plasma membranes that surrounded excitatory synapses were included in the study. EAAT2 has been shown to be selectively located in astrocytic membranes (Chaudhry et al. 1995) . A synapse was defined as excitatory when it contained an asymmetric synaptic specialization and/or high levels of glutamate in the presynaptic terminal (above twice the glutamate levels in dendrites). Glutamate and D-serine immunogold particles and grid points for area determination (see below) were recorded over SLMVs in EAAT2-positive astrocytic processes, over SVs in excitatory nerve terminals, and over cytoplasmic matrix (areas free of vesicles and mitochondria in the astrocytes and nerve terminals). SLMVs and SVs were included in the analysis if they had a diameter ranging from 20 to 80 nm (this study, Gundersen et al. 1998; Bezzi et al. 2004) . As the lateral resolution of the current immunogold method ( Supplementary Fig. 3 ) is similar to the diameter of the SLMVs, the method cannot localize a gold particle to a single vesicle. Thus, epitopes within SVs may be signaled by gold particles outside the vesicles and vice versa. To bypass this problem, gold particles were ascribed to the SLMVs and SVs if the particle centers were inside the vesicles or located in the cytoplasmic matrix within a 30 nm distance from the outer border of the vesicles. This is a distance within which most of the immunogold particles are expected to occur. Details of these criteria are given in Supplementary Figure 3 (see also Chaudhry et al. 1995; Matsubara et al. 1996) . Using this criterion, a gold particle was ascribed to a vesicle if the center of the particle was located within an area defined by a boundary drawn 30 nm from the vesicle membrane (see Supplementary Fig. 3 ). Particles located outside of this ''vesicle area'' were assigned to the cytoplasmic matrix. To correct for the contamination of the vesicle labeling with the cytoplasmic matrix labeling, the gold particle densities recorded over cytoplasmic matrix were subtracted from the gold particle densities recorded for the vesicles. The areas of the profiles included in the analysis were determined by point counting using an overlay screen (Bergersen et al. 2008) . The densities of glutamate and D-serine immunogold particles (average number of gold particles/square micrometer) in the different tissue profiles were calculated, and the results statistically evaluated by a nonparametric test (Mann--Whitney U, Statistica). To sum up, we counted the number of glutamate and D-serine gold particles belonging to individual vesicles and estimated the total area that individual vesicles occupy in a profile, thus obtaining a measure of the density of gold particles per vesicle area.
The spatial relationships between gold particles signaling: 1) D-serine (10 nm) or glutamate (10 nm) and VGLUT1 (15 nm); 2) D-serine (10 nm) and glutamate (15 nm); and 3) calreticulin (10 nm) or caveolin-1 (10 nm) and VGLUT1 (15 nm) in morphologically identified astrocytic processes and excitatory nerve terminals were determined by a computer program (http://rsb.info.nih.gov/ij/). The intercenter distances between the 10 and 15 nm gold particles were calculated, and the distances were sorted into bins of 20 nm. The frequency distributions were evaluated by a chi-squared test (Statistica) .
The relationship between the density of glutamate and D-serine immunogold particles and the concentration of fixed glutamate and Dserine in the tissue was close to linear, as assessed by simultaneously processed test sections with conjugates containing known concentrations of glutamate (Ottersen 1989a ) and D-serine (see Supplementary Fig. 4) . Similar relationships between the density of gold particles signaling glutamate and the concentration of glutamate in the test conjugates as found in the present investigation have been described previously (Ottersen 1989a; Bramham et al. 1990 ). The D-serine--graded test conjugates were made as previously described for graded D-aspartate sections (Gundersen et al. 1995) . In brief, slabs of 7% gelatin and 10% human serum albumin (HSA) with known areas were incubated in 10% HSA at various concentrations of D-serine (0, 0.33, 1, 3, 9, and 27 mM) before immersing in the tissue fixative (2.5% glutaraldehyde and 1% formaldehyde) for 1 h. The fixed blocks were then embedded in Durcupan. The concentrations of D-serine in the conjugate slabs after fixation (but before embedding) were determined by liquid scintillation counting using tracer amounts of D-3 H-serine (Perkin Elmer). Hence, the particle density in tissue compartments could be compared with those over the different D-serine conjugates.
Results
Synaptic-Like Microvesicles
We analyzed astrocytes in the hippocampal dentate molecular layer of adult rats. At first, we used a preparation optimized for morphologic visualization of membrane-bounded structures (tissue fixed with high glutaraldehyde concentration, postfixed with osmium tetroxide, and embedded in epoxy resin) to quantify vesicular organelles in delicate astrocytic processes surrounding excitatory synapses. The perisynaptic astrocytic processes (average cross-sectional diameters of 429 ± 195 nm [standard deviation {SD}, n = 48]) were identified by their concave shape and low electron density (Lehre and Danbolt 1998) . Figure 1 shows that these processes contain vesicles resembling SVs. They are small (average diameter of about 36 nm, Fig. 1c) , clear, and round/oval, justifying the term SLMV 2 ± SD) either in the entire astrocytic process (n 5 48) and nerve terminal (n 5 18) profiles or specifically in vesicle clusters in astrocytic processes (n 5 48) and in the synaptic vesicle pool located \100 nm from the nerve terminal active zone (n 5 18) (see also Supplementary Fig. 1 ). *, the value for SV is significantly higher than the value for SLMV (P \ 0.01, Mann--Whitney U test, two tails). (Bezzi et al. 2004; Jourdain et al. 2007 ). The SLMVs were found to be present in the majority (67%) of the observed processes, with a nonrandom distribution throughout the cytoplasm. They were situated in small clusters of 2--15 vesicles (Figs 1a,b and 2) and were preferentially located at or near the astrocytic plasma membrane (maximal frequency within 50 nm from the membrane, Fig. 1d ). In profiles containing more than one cluster, the average intergroup distance was 340 ± 209 nm (SD, n = 350 clusters). The average density of SLMVs in an astrocytic profile was about one-tenth of the density of SVs in excitatory terminals (Fig. 1e) , but within the area delimiting an astrocytic cluster, the density of SLMVs was about one-half of the density of SVs located in proximity (within 100 nm) of the presynaptic membrane active zone (Figs 1f and 2 ; for detailed quantitative analysis of SLMVs in perisynaptic processes, see Supplementary Result 1).
Quantitative Immunogold Cytochemistry
We then continued our investigations on tissue prepared for optimal immunogold sensitivity (tissue treated with uranyl acetate and embedded in Lowicryl). In this case, astrocytic processes were identified and selected for analysis not only according to the morphological criteria indicated above but also based on the membrane labeling for the astrocytic glutamate transporter EAAT2/GLT1. Small clusters of SLMVs located at or near the astrocytic membrane ( Supplementary  Fig. 2 ) were visible also in this preparation, and individual vesicles could be reliably recognized (Supplementary Result 2) , even though their membranes were less distinct than the SV membranes. We therefore tested whether SLMVs contain glutamate and D-serine by use of specific antibodies against the 2 amino acids. The protocol for attributing glutamate and D-serine immunogold particles to vesicles or to the cytoplasmic matrix is given in Materials and Methods (section on morphological and immunogold analysis). Using this approach, we could show that astrocytic SLMVs contain immunogold particles signaling glutamate and D-serine (Fig. 2) . This conclusion was reinforced by the observation that most of the immunogold particles signaling glutamate and D-serine were located <100 nm from the astrocytic plasma membrane and followed the SLMV distribution ( Supplementary Fig. 5 ).
The density of glutamate immunogold particles over the SLMVs was much higher than the density in the cytoplasmic matrix of the astrocytes and only slightly lower than the density over SVs in adjacent excitatory nerve terminals. The particle density in the cytoplasmic matrix of the astrocytes was, in turn, lower than that in the cytoplasmic matrix of nerve terminals (Fig. 2a--c) . To assess the degree of glutamate accumulation in the vesicles, we calculated the ratio of glutamate labeling between the vesicles and the cytoplasmic matrix. This ratio was higher between SLMV/ astrocytic cytoplasmic matrix than between SVs/terminal cytoplasmic matrix (22 vs. 6; see Supplementary Result 3 for a control of the fixation efficiencies of free amino acids at protein-rich vs. nonprotein-rich sites in the tissue). The bar charts show the mean number of glutamate and D-serine gold particles/lm 2 ± SD in SLMVs and the cytoplasmic matrix of astrocytic processes (Acyt) in n 5 3 animals. In addition, we show the density of glutamate gold particles in nerve terminals over SVs and the cytoplasmic matrix (Tcyt). Background glutamate and D-serine labeling over empty resin (0.9 and 0.8 gold particles/lm 2 , respectively) were subtracted. The numbers of astrocytic processes and nerve terminals included in the glutamate analysis from each animal were 44--50 and 13--21, respectively, while the numbers of astrocytic processes included in the D-serine analysis from each animal were 25--28. *, the glutamate values in SV and SLMV are significantly higher than the values in Tcyt and Acyt, respectively (P \ 0.001, Mann--Whitney U test, two tails). §, the glutamate value in SV is significantly higher than the value in SLMV (P \ 0.05, Mann--Whitney U test, 2 tails). #, the D-serine value in SLMV is significantly higher than the value in Acyt (P \ 0.001, Mann--Whitney U test, two tails).
As previously reported, D-serine labeling was observed in astrocytic processes (Schell et al. 1995; Williams et al. 2006) (Fig. 2d,e) . Gold particles representing D-serine were associated with the SLMVs rather than with the cytoplasmic matrix (Fig. 2f) . The ratio of D-serine gold particle density between SLMV and cytoplasmic matrix of the astrocytes was 8, suggesting a considerable accumulation of D-serine in the SLMVs. In addition, nerve terminals exhibited a rather weak D-serine signal with no clear association to vesicular structures (Kartvelishvily et al. 2006 ) (for details of the intraterminal distribution of D-serine, see Supplementary Result 4).
The approximate concentration of glutamate and D-serine in the different tissue profiles was estimated by calibration with known concentrations of glutamate and D-serine (see Supplementary Fig. 4 ). The glutamate gold particle densities corresponded to a concentration of glutamate of~50--60 mM in SLMVs and SVs and of~2 and~10 mM in the cytoplasmic matrix of the astrocytes and the nerve terminals, respectively. For Dserine, we estimated that the concentration of fixed D-serine in the SLMVs was~10 mM, whereas the D-serine concentration in the astrocyte cytoplasmic matrix was~1 mM.
To investigate whether glutamate and D-serine are contained in the same pool of SLMVs, we performed double labeling with the glutamate and D-serine antibodies. In none of the investigated astrocytic processes was there any clear evidence of colocalization of the 2 amino acids in the same SLMV (Fig. 3a,e) . Likewise, colabelling with D-serine and VGLUT1 antibodies did not reveal any clear colocalization (Fig. 3b,f) , whereas, as expected, there were several examples of glutamate and VGLUT1 gold particles associated with the same SLMV as well as with SVs (Fig. 3c,g, and  h ). It should, however, be noted that the D-serine and VGLUT1 antibodies produced a relatively low immunolabeling of SLMVs, which could have led to an underestimation of D-serine/ glutamate and D-serine/VGLUT1 double labeling. Thus, we cannot totally exclude a partial colocalization of D-serine and glutamate in the same vesicle pool.
Exocytosis of SLMVs in astrocytes has been proposed to occur upon Ca 2+ mobilization from the endoplasmic reticulum (ER) (Marchaland et al. 2008) . We checked the presence of ER tubules in the perisynaptic astrocytic processes and their spatial relation with SLMVs. Antibodies against the ER marker calreticulin labeled elongated tubular structures, mostly in neuronal dendritic profiles, but also in astrocytic processes ( Fig. 3d,i; Supplementary Fig. 6 ). VGLUT1 and calreticulin double labeling suggest that the astrocytic processes are equipped with ER located close to (within 100--200 nm), but not overlapping with, glutamate-containing SLMVs (Fig. 3d) . Astrocytic processes were also endowed with membranebounded structures labeled for caveolin-1. Double labeling for VGLUT1 and caveolin-1 (Supplementary Fig. 7) showed no significant colocalization, suggesting that astrocytic processes contain several pools of vesicle-like organelles that may serve separate functions, such as storage of transmitters, storage of Ca
2+
, and caveola-mediated endocytosis.
Discussion
The present immunogold data from perisynaptic astrocytic processes provide the first direct evidence that the putative gliotransmitters glutamate and D-serine are stored in astrocytic SLMVs in situ in the adult brain. The presence in the fine perisynaptic processes of clusters of transmitter-containing SLMVs at or near the astrocytic membrane, together with spatially related ER tubules, is a prerequisite for precise astrocyte-to-neuron communication. Indeed, these ultrastructural observations support functional data showing that activation of endogenous G protein-coupled receptors on astrocytes induces glutamate receptor--dependent and tetanus toxin sensitive presynaptic modulation in situ (Jourdain et al. 2007; Perea and Araque 2007) and that astrocytes display a glutamate exocytosis process tightly regulated by TNF-a . Moreover, our data are in line with the recent observation that selective dialysis of tetanus toxin in astrocytes prevents LTP induction at neighboring synapses by blocking D-serine release (Henneberger et al. 2010) . Tetanus toxin is an exocytosis blocker acting on VAMP3/cellubrevin, which is expressed in SLMVs (Bezzi et al. 2004 ). The present and previous observations in support of astrocytic transmitter exocytosis were made in the hippocampus. However, the conclusions are likely to be more generally valid as VGLUT1 is closely associated with SLMVs also in several other brain regions, including frontal cortex and striatum (L Ormel, LH Bergersen, V Gundersen, unpublished data) . It should also be noted that in freshly isolated astrocytes, recent observations show that, unlike lysosomal vesicles, small vesicles in astrocytes exocytose glutamate in a vesicular glutamate transporter--dependent manner (Liu et al. 2011) , which is in strong support of our data on glutamate localization in astrocytic SLMVs.
Our present data also reveal an important number of similarities between glutamate-containing SLMVs in astrocytic processes and SVs in excitatory nerve terminals. Not only are SLMVs similar to SVs in size and shape, as previously reported (Bezzi et al. 2004 ), but also in glutamate content, which is here estimated in astrocytes for the first time, and in localization with respect to the astrocytic plasma membrane. Thus, most astrocytic SLMVs are as close to the plasma membrane as the readily releasable pool of SVs in nerve terminals (Gitler et al. 2004; Owe et al. 2009 ), consistent with the possibility that a proportion of astrocytic SLMVs is docked and competent for fast fusion in response to stimuli. The organization of SLMVs in astrocytic processes seems different from the grouping of a large SV population in nerve terminal structures. In particular, in the nerve terminals, there appears to be an accumulation of distinct pools of SVs, with a large reserve pool (80--90% of the vesicles) mostly located in the core region of the terminal and linked to the cytoskeleton by synapsin--actin interactions (Owe et al. 2009 ). Interestingly, hippocampal excitatory nerve terminals of synapsin-lacking mice display selective reduction in the density of this large pool, whereas the small readily releasable/recycling pool ( <100 nm from the plasma membrane) remains largely intact (Gitler et al. 2004; Owe et al. 2009 ). The presence of distinct pools is not apparent in astrocytes, as SLMVs are all regrouped within 100 nm from the membrane, suggesting that astrocytes lack a defined reserve pool. This hypothesis seems plausible because mobilization of the reserve pool at synapses is triggered only during high-frequency neuronal activity. In astrocytes, exocytosis of SLMVs is evoked by activation of G protein--coupled receptors and even if the stimulus--secretion coupling can occur within 50--100 ms (Bezzi et al. 2004; Domercq et al. 2006; Marchaland et al. 2008) , this signaling mode is not tailored for high-frequency encoding. Lack of a large reserve pool would explain both the significantly lower number of vesicles found in astrocytic processes compared with nerve terminals and their low electron density due to reduced protein--protein interactions. Moreover, we found that astrocytic processes are equipped with ER located close to glutamatecontaining SLMVs. This subcellular arrangement could constitute a functional nanodomain in which local increases in Ca 2+ concentration from the internal stores trigger release of glutamate from SLMVs (Marchaland et al. 2008) . Ca 2+ microdomains have been observed in astrocyte cultures (Lee et al. 2006; Shigetomi et al. 2010) , and in addition to controlling transmitter release, it has been proposed that such domains may be involved in local volume regulation in astrocytes (Akita and Okada 2011) . In the cerebellum, neuronal stimulation has been shown to trigger Ca 2+ increase in Bergmann glial cells at distinct microdomains (Grosche et al. 1999) . Moreover, very recent evidence in the adult dentate gyrus shows that astrocytic processes respond to local synaptic events with highly confined Ca 2+ elevations that, in turn, participate to the control of transmitter release at local synapses (Di Castro et al. 2011) , strongly supporting the view that these astrocyte domains represent local sites at which astrocyte-neuron signaling occurs.
The present study provides estimated values of the vesicular and cytosolic glutamate concentrations in nerve terminals and astrocytes. The values in SVs and in the cytoplasmic matrix of nerve terminals are in good agreement with previous estimates (Burger et al. 1989; Shupliakov et al. 1992) . The glutamate concentration that we find in the cytosolic matrix of astrocytic processes is in the lower millimolar range, a concentration which can sustain glutamate uptake into SLMVs according to the reported Km of VGLUT-mediated vesicular uptake (Fremeau et al. 2004) . As the glutamate ratios between vesicles and cytosolic matrix were different in nerve terminals and astrocytes, there may be some differences in the mechanisms regulating the filling of SLMVs and SVs. Indeed, mechanisms similar to those discovered to operate in dopaminergic (Brunk et al. 2006 ) and cholinergic (Gras et al. 2008) vesicles could contribute to regulate glutamate uptake into astrocytic SLMVs. An intriguing aspect of exocytosis regulation is whether VGLUTs are inserted into plasma membranes to function as phosphate transporters. However, we could not observe any immunogold signal for VGLUT1 in plasma membranes, neither in astrocytes nor in nerve terminals (LH Bergersen, V Gundersen, unpublished data) .
Our findings regarding D-serine are intriguing. The labeling pattern in astrocytic processes strongly suggests a vesicular localization of D-serine (see also Williams et al. 2006) . However, the VGLUTs do not carry D-serine, suggesting that there is a vesicular transporter for D-serine that remains to be identified. D-serine is present in a population of astrocytic SLMVs structurally indistinguishable from the one storing glutamate. However, SLMVs containing D-serine and glutamate do not appear to overlap to any considerable extent. Yet, both glutamate-containing and D-serine--containing SLMVs are present in the same very fine astrocytic processes and are in the position of discharging their amino acid content into the perisynaptic area surrounding excitatory synapses on granule cell dendrites. It has been shown that glutamate released by exocytosis from astrocytes produces presynaptic NMDA receptor responses, which in turn strengthen the excitatory synaptic response at granule cell synapses (Jourdain et al. 2007 ). In addition, our results suggest that exocytosis underlies the astrocytic glutamate release detected by electrophysiology in stratum radiatum of CA1 hippocampus (Kang et al. 1998; Fiacco et al. 2004; Andersson et al. 2007; Andersson and Hanse 2010) and the cortex (Wirkner et al. 2007 ). There are several lines of evidence suggesting that release of D-serine from astrocytes can regulate neuronal NMDA receptors. In intact brain tissue, it is known that astrocytic D-serine release controls the level of activation of synaptic NMDA receptors and thereby long-term synaptic signaling in the hypothalamus (Panatier et al. 2006 ) and CA1 hippocampus (Henneberger et al. 2010) . Likewise, in the retina, it is known that glial cell--derived D-serine can enhance NMDA receptor responses (Stevens et al. 2003) . Using a combination of neurons and astrocytes in culture and hippocampal slices, Yang et al. (2003) found that D-serine released from astrocytes enhanced neuronal NMDA receptor currents and triggered LTP. Interestingly, the release of D-serine from astrocytes can be subjected to regulation, for example, by ephrinBs (Zhuang et al. 2010 ).
In conclusion, we propose that the joint or separate release of glutamate and D-serine from astrocytes could provide a sophisticated control of the activity of neuronal NMDA receptor populations.
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